Maegim한국어

옵투스제약

131030KOSDAQSector: Pharma & Biotech
₩5,460▼ 10.49%Market cap ₩96.4BAs of Jul 21, 2026 close · updated once daily
A
Grade A76.4 ptsTop 3% of 2,523 stocks
Financial strength
76.3
Growth momentum
63.3
Price attractiveness
85.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

76.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
15.8%
✓ Above median · Top 16.5% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
262.3%
✓ Above median · Top 37.2% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
10.2%
✓ Above median · Top 19.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
6.9%
✓ Above median · Top 22.2% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

63.3
How much did revenue grow in a year?
Revenue growth (YoY)
6.4%
✗ Below median · Top 50.5% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
14.1%
✓ Above median · Top 23.4% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
3.3%
✗ Below median · Top 50.7% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
68.8%
✓ Above median · Top 22.3% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

85.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
8.5x
✓ Above median · Top 11.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.58x
✓ Above median · Top 17.3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15